Abstract
Exposure to Clostridioides difficile can result in asymptomatic carriage or infection with symptoms ranging from mild diarrhea to fulminant pseudomembranous colitis. A reliable diagnostic approach for C. difficile infection (CDI) remains controversial. Accurate diagnosis is paramount not only for patient management but also for epidemiology and disease research. Here, we characterized gut microbial compositions and a broad panel of innate and adaptive immunological markers in 243 well-characterized human subjects, who were divided into four phenotype groups: CDI, Asymptomatic Carriage, Non-CDI Diarrhea, and Control. We found that CDI is associated with alteration of many different aspects of the gut microbiota, including overall microbial diversity and microbial association networks. We demonstrated that incorporating both gut microbiome and host immune marker data into classification models can better distinguish CDI from other groups than can either type of data alone. Our classification models display robust diagnostic performance to differentiate CDI from Asymptomatic carriage (AUC~0.916), Non-CDI Diarrhea (AUC~0.917), or Non-CDI that combines all other three groups (AUC~0.929). Finally, we performed symbolic classification using selected features to derive simple mathematic formulas for highly accurate CDI diagnosis. Overall, this study provides evidence supporting important roles of gut microbiota and host immune markers in CDI diagnosis, which may also inform the design of future therapeutic strategies.
One Sentence Summary Incorporating both gut microbiome and host immune marker data into classification models can better distinguish CDI from other groups than can either type of data alone.
Competing Interest Statement
C.P.K. has acted as a paid consultant to Artugen, Facile Therapeutics, First Light Biosciences, Finch, Matrivax, Merck, Seres Health, and Vedanta and has received grant support from Merck. X. C. has acted as a paid consultant to Artugen. All other authors report no potential conflicts of interest.
Funding Statement
Y.-Y.L. acknowledged grants from National Institutes of Health (R01AI141529, R01HD093761, UH3OD023268, U19AI095219 and U01HL089856). N.R.P. and C.P.K. acknowledged grants from National Institutes of Health (R01AI116596) and Institut Mérieux. S.K. was supported by the China Scholarship Council.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available from corresponding authors upon reasonable request.